Selank is a synthetic heptapeptide created by combining the sequence of the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg) with an additional tripeptide fragment (Pro-Gly-Pro) to enhance metabolic stability. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences.
The N-Acetyl (NA) form provides additional protection against enzymatic degradation, further extending the peptide’s stability in biological systems.
Preclinical and clinical research has investigated Selank across models of anxiety, immune function, and GABAergic neurotransmission. A key human clinical trial involving 62 patients with generalised anxiety disorder reported anxiolytic effects comparable to the benzodiazepine medazepam, while additionally describing antiasthenic and psychostimulant observations without sedation, muscle relaxation, tolerance, or withdrawal.
Molecular studies have identified marked changes in GABA receptor subunit expression following Selank administration, including approximately 20-fold modulation of specific receptor subunit transcripts. A 2020 human neuroimaging (fMRI) study in 52 healthy participants demonstrated measurable changes in functional connectivity patterns centred around the amygdala, providing objective neuroimaging evidence for mechanism-focused research.
For In-Vitro Research Use Only. Not for human consumption, veterinary use, or clinical application. No dosing guidance is provided or implied.




